Treatment | Day of study | |||||
---|---|---|---|---|---|---|
9 | 16 | 23 | 30 | 37 | ||
Placebo | Range | 17–26 | 20–28 | 15–26 | 21–27 | 19–26 |
Arithmetic mean (AM) | 21.00 | 24.13 | 22.00 | 22.88 | 22.25 | |
Geometric mean (GM)a | 20.79 | 23.98 | 21.69 | 22.80 | 22.15 | |
Sarolaner | Range | 0–0 | 0–2 | 0–2 | 0–3 | 0–1 |
Arithmetic mean (AM) | 0 | 0.38 | 0.50 | 1.25 | 0.25 | |
AM Efficacy (%) | 100 | 98.45 | 97.73 | 94.54 | 98.88 | |
G. mean (GM)a | 0 | 0.25 | 0.32 | 1.03 | 0.19 | |
GM Efficacy (%) | 100 | 98.95 | 98.54 | 95.48 | 99.15 | |
Test statistic vs placebo | t (19) = 54.50 | t (25) = 20.30 | t (19) = 13.13 | t (23) = 12.78 | t (26) = 21.67 | |
P-value vs placebo | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | |
Afoxolaner | Range | 0–0 | 0–1 | 0–4 | 0–2 | 0–1 |
Arithmetic mean (AM) | 0 | 0.13 | 1.50 | 0.38 | 0.25 | |
AM Efficacy (%) | 100 | 99.48 | 93.18 | 98.36 | 98.88 | |
G. mean (GM)a | 0 | 0.09 | 1.28 | 0.25 | 0.19 | |
GM Efficacy (%) | 100 | 99.62 | 94.12 | 98.90 | 99.15 | |
Test statistic vs placebo | t (19) = 54.50 | t (25) = 21.23 | t (19) = 10.60 | t (23) = 15.29 | t (26) = 21.67 | |
P-value vs placebo | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | |
Test statistic vs sarolaner | t (19) = 0.00 | t (25) = 0.93 | t (19) = 2.53 | t (23) = 2.51 | t (26) = 0.00 | |
P-value vs sarolaner | 1.0000 | 0.3606 | 0.0204 | 0.0195 | 1.0000 |